Drug Profile
Paclitaxel - Angiotech
Alternative Names: Cremophor EL-free paclitaxel - Angiotech; Eluvia; Formula PTX; Innova; Micellar paclitaxel; Paxceed; TAXUS Element; TAXUS Express2; TAXUS Liberte; TAXUS Petal; Vascular Wrap; Zilver PTXLatest Information Update: 04 Nov 2017
Price :
*
At a glance
- Originator Angiotech Pharmaceuticals
- Developer Angiotech Pharmaceuticals; Boston Scientific Corporation; Broncus Technologies; Cook Medical
- Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
- Mechanism of Action Angiogenesis inhibitors; Immunosuppressants; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Coronary artery restenosis; Myocardial infarction; Vascular restenosis
- No development reported Emphysema
- Discontinued Alzheimer's disease; Cancer; Multiple sclerosis; Oesophageal cancer; Post-surgical adhesions; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Vascular-restenosis in Europe (Intra-arterial)
- 31 Mar 2017 Cook Medical completes a clinical trial in Vascular restenosis in China (NCT02171962)
- 01 Feb 2017 Boston Scientific completes the phase II MAJESTIC trial in Vascular restenosis in New Zealand, Germany, Belgium, Austria, Australia (Intra-arterial) (NCT01820637)